Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Monotherapy vs Aflibercept + PDT in PCV
NCT02120950Phase 4Completed
- Sponsor
- Bayer
- Start
- May 2014
- Primary completion
- Aug 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 4 trial of aflibercept in polypoidal choroidal vasculopathy (PCV), sponsored by Bayer. Started May 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT02120950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120950.